32 Biosciences "Three Squared"

The gut microbiome has long been overlooked in clinical practice, but 32 Biosciences "Three Squared" is on a mission to change that. 🧬 Under the leadership of CEO Peter Farmakis, 32 Biosciences is developing diagnostic tools and microbiome-based interventions that could revolutionize how we treat chronic diseases. Backed by groundbreaking research and significant non-dilutive funding, 32 Biosciences is addressing a massive unmet need in healthcare. Their vision? To make the gut microbiome a cornerstone of modern medicine, improving health outcomes and extending healthspan. Read our latest founder profile: https://buff.ly/4gCx77O

Thank you Léa Bouhelier-Gautreau and Kingscrowd for your fantastic interview of 32 Biosciences "Three Squared" CEO Peter Farmakis! You can read the entire interview Here: https://lnkd.in/ejM53xDv If you are interested in participating in our investment opportunity, please contact Peter Farmakis by Dec 20, 2024.

We’re excited to spotlight Joseph F. Pierre, PhD, a scientific co-founder of 32 Biosciences "Three Squared" Biosciences, where he develops science-based nutritional products to support gut health. As an assistant professor in the Departments of Nutritional Sciences and Surgery at UW–Madison, Dr. Pierre’s research examines how diet, gut physiology, and the microbiome influence health and disease. Dr. Pierre’s academic journey includes: Postdoctoral Fellowship at the University of Chicago (2013–2017): Mentored by Eugene Chang, MD (Chang MED) where he collaborated on the groundbreaking diagnostic platform for 32 Biosciences "Three Squared" Biosciences, earning recognition as a scientific co-founder. Postdoctoral Scholar at UW–Madison (2012–2013): Studied dietary effects on mucosal immunity with Kenneth A. Kudsk, MD. Graduate Research Assistant at UW–Madison (2009–2012): Built a foundation in gastrointestinal research through the Nutritional Sciences program. Dr. Pierre’s research program spans dairy science, microbiome studies, and nutritional science, employing cutting-edge methods like gnotobiotics and organoid models. Current NIH-funded projects explore bariatric surgery’s impact on breast cancer and microbial influences on cardiovascular health and inflammatory bowel disease. A Wisconsin native, Dr. Pierre exemplifies the Wisconsin Idea, using research to benefit communities locally and globally. Follow his journey on Joseph F. Pierre or 32 Biosciences "Three Squared"! #GutHealth #NutritionScience #MicrobiomeResearch #UWFacultySpotlight

32 Biosciences is tackling some of the biggest challenges in gut health, led by world-renowned experts in microbiome medicine. A new video highlights the critical issues faced by patients with gut health problems, the gaps in diagnostic tools, and the groundbreaking research our team is leading to deliver real, actionable solutions. https://lnkd.in/eZdxVmYM With the potential to impact over 20 million Americans, 32 Biosciences is poised to revolutionize how we measure health, prevent chronic diseases, and develop targeted interventions—ultimately creating a healthier future for all. Check out the video to learn more about this exciting work! Message Peter Farmakis to learn more about investing. #GutHealth #Microbiome #Innovation #HealthyFuture #ChronicDiseasePrevention

Why do surgical site infections (SSIs) still happen, despite decades of effort and huge investments in prevention? John Alverdy, MD, a world-renowned expert on SSIs, has spent his career seeking answers. In a recent JAMA Surgery article, he dives into the current standard of care and proposes new strategies to tackle drug-resistant SSIs—highlighting the often-overlooked role of the gut microbiome in their origin. At 32 Biosciences, we're taking this research further with a groundbreaking, non-antibiotic anti-infective drug developed by Dr. Alverdy. Designed to collaborate with the gut microbiome, this drug aims to reduce SSI incidence while avoiding the spread of antimicrobial resistance. A smarter, safer future for surgical outcomes could be just around the corner. #SSI #Microbiome #AntimicrobialResistance #SurgicalInnovation #HealthTech #GutHealth

A New, Quantitative Way to Measure Gut Microbiome Health In healthcare, there are tests for analyzing the state of health, such as cholesterol, blood pressure, and glucose levels. Yet, there has been no quantitative measure for the gut microbiome, which is increasingly recognized as a vital organ alongside the brain, lungs, heart, liver, and kidney. At 32 Biosciences "Three Squared" Biosciences, we are transforming how gut microbiome health is assessed and treated. Precision is Key: Our diagnostic platform analyzes 20 metabolites to deliver a first-of-its-kind quantitative measure of gut health. The results are easy to understand for both doctors and patients, enabling personalized interventions—nutritional and medical—to improve health outcomes. Innovative Therapeutics: We are also developing a groundbreaking therapy to prevent infections without the need for antibiotics. If approved, this simple, odorless powder could significantly reduce the risk of surgical site infections, C. diff., sepsis, and chemotherapy-related toxicities and infections. Patients simply mix it with water and consume it three days before and after surgery. A Trusted Network of Support We are proud to have the backing of prestigious institutions, including the Duchossois Family Institute, Pritzker School of Molecular Engineering at the University of Chicago, University of Wisconsin-Madison and $119 million in funding that our scientific founders have received from The National Institutes of Health. Their support validates the importance of the research and development work conducted by Dr. Eugene B. Chang(Chang MED), Dr. John C. Alverdy, and Dr. Joseph F. Pierre.  Engage With Us If you're interested in our innovative work or potential investment opportunities, please feel free to message me. Thank you for your interest in our mission to revolutionize gut microbiome medicine! Best, Peter Farmakis CEO, 32 Biosciences #GutHealth #Microbiome #PrecisionMedicine #Biotechnology #InfectionPrevention

Important Research Connecting the Gut Microbiome and Childhood Growth! We continue to uncover the complexities of the gut microbiome in a recent study in iScience, led by notable researcher Dr. Eugene Chang (Chang MED), illustrating how the gut microbiome is vital for the normal growth and development of the nerves that govern gut function from birth. https://lnkd.in/erVbk8W3 These findings open new avenues for innovative diagnostics, treatments, and preventive strategies, enriching our understanding of normal physiology. At 32 Biosciences "Three Squared" Biosciences, we continue to harness our expertise in the intricate interactions between the human body and the gut microbiome to develop cutting-edge solutions that propel the field of Microbiome Medicine forward. If you're eager to explore the future of healthcare and innovation, we invite you to follow us on LinkedIn and visit us at 32biosciences.com. A heartfelt thank you to Dr. Chang for his pioneering contributions to this vital research! Chang MED #GutHealth #MicrobiomeMedicine #HealthcareInnovation #32Biosciences #ResearchAndDevelopment #innovation #Microbiome

Exciting Times at 32 Biosciences! As CEO, I couldn't be prouder of our team's dedication and tireless efforts. Our hard work has garnered significant recognition, with research from our scientific founders featured in prestigious publications like Science, Cell, and the American Journal of Surgery, highlighting our impact in gut microbiome medicine. Addressing a Critical Need: We are developing the first scientific method to diagnose complex gut microbiome issues—a challenge affecting over 60 million Americans. For the first time, clinicians will be able to accurately identify these issues and recommend targeted nutritional and medical interventions. This innovation has vast potential applications, including for Irritable Bowel Syndrome, Parkinson's, prevention of surgical site infections, sepsis, colon cancer, and more. Transformative Research: Backed by $119 million in NIH funding, our research is set to change how we understand and treat gut health. We are at the forefront of scientific advancement, literally changing the way human health is measured. Let’s Connect: I invite you to engage with me—share your thoughts, ideas, and questions. Together, we can enhance our understanding of gut microbiome health, along with better prevention techniques and effective therapies. Investment Opportunity: If you’re interested in investing in the future of gut microbiome health through 32 Biosciences, please message me directly! Thank you for being part of our journey to better gut health. Kind regards, Peter Farmakis CEO, 32 Biosciences #guthealth #gutmicrobiome #gutmicrobiomeresearch #infectionprevention

A special thank you to the @University of Chicago Polsky Center for Entrepreneurship and Innovation for shining a spotlight on Drs. Gene Chang and John Alverdy as two of the scientific founders of 32 Biosciences in their recent article! Their groundbreaking work is further underscored by the impressive $119 million in NIH grants, which have led to 650 peer-reviewed publications among our scientific co-founders. It’s inspiring to see how collaboration in the microbiome space is driving innovation and amplifying research outcomes. Check out the full article here: https://lnkd.in/gSsD2J-i #Entrepreneurship #Microbiome #Innovation #ScientificResearch #Gratitude

🌍 September is National Sepsis Awareness Month, a crucial time to shed light on a serious public health challenge. Sepsis, the body’s extreme response to infection, affects 1.7 million people annually in the U.S., claiming 350,000 lives each year—more than prostate cancer, breast cancer, and opioid overdose combined. At 32 Biosciences, we’re dedicated to combating this crisis.  We are thrilled to announce that Dr. John Alverdy and the Alverdy Lab has received a $400,000 NIH – NCI STTR Phase I grant for our innovative CS Platform Technology. This grant, titled “Preventing chemotherapy-related toxicities and infections with a novel phosphorylated triblock copolymer,” highlights the potential of our technology in reducing infections, such as surgical site infections and sepsis, and preventing the toxicities and infections often associated with chemotherapy. As we raise awareness this month, let’s remember: Infection Prevention is Sepsis Prevention™. Together, we can spread the word about sepsis, promote awareness, and support groundbreaking research that aims to save lives. Join us in making a difference! 💙 Learn more about our innovative CS Platform Technology by viewing the image below. #SepsisAwarenessMonth #GutMicrobiome #32Biosciences #GutHealth #InfectionPrevention